Abstract

BackgroundDrugs that bind to the human Ether-a-go-go Related Gene (hERG) potassium channel and block its ion conduction can lead to Torsade de Pointes (TdP), a fatal ventricular arrhythmia. Thus, compounds are screened for hERG inhibition in the drug development process; those found to be active face a difficult road to approval. Knowing which structural transformations reduce hERG binding would be helpful in the lead optimization phase of drug discovery.ResultsTo identify such transformations, we carried out a comprehensive analysis of all approximately 33,000 compound pairs in the Novartis internal database which have IC50 values in the dofetilide displacement assay. Most molecular transformations have only a single example in the data set; however, a few dozen transformations have sufficient numbers for statistical analysis.ConclusionsWe observe that transformations which increased polarity (for example adding an oxygen, or an sp2 nitrogen), decreased lipophilicity (removing carbons), or decreased positive charge consistently reduced hERG inhibition between 3- and 10-fold. The largest observed reduction in hERG was from a transformation from imidazole to methyl tetrazole. We also observe that some changes in aromatic ring substituents (for example hydrogen to methoxy) can also reduce hERG binding in vitro.

Highlights

  • Drugs that bind to the human Ether-a-go-go Related Gene potassium channel and block its ion conduction can lead to Torsade de Pointes (TdP), a fatal ventricular arrhythmia

  • To identify transformations that have a Wilcoxon consistent effect on human Ether-a-go-go Related Gene (hERG) inhibition, we introduce fingerprint pairs, which are an extension of the Structure-activity landscape index (SALI) approach

  • Each aggregate is summarized by its mean hERG inhibition and the number of pairs in the aggregate (Figure 2)

Read more

Summary

Introduction

Drugs that bind to the human Ether-a-go-go Related Gene (hERG) potassium channel and block its ion conduction can lead to Torsade de Pointes (TdP), a fatal ventricular arrhythmia. Inhibition of the human Ether-a-go-go Related Gene (hERG) channel can be a limiting toxicity for drug candidates. Inhibition of the hERG channel causes lengthening of the cardic QT interval, which can lead to Torsade de Pointes (TdP) [2]. It was this toxicity that in 1997 led to the withdrawal of terfenadine (Seldane) [3]. The frequency and severity of hERG inhibition drives drug discovery teams to make considerable efforts in measuring, analyzing, and mitigating hERG inhibition [4]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call